Adalvo announces the DCP approval of Riociguat Tablets, a therapy designed to treat pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).
As a first-in-class soluble guanylate cyclase (sGC) stimulator, Riociguat has become the first globally approved pharmacotherapy for CTEPH, addressing a gap in the treatment of cardiovascular conditions.
Clinical studies have shown Riociguat’s ability to deliver meaningful outcomes, including improvements in exercise capacity and pulmonary vascular hemodynamics (European Respiratory Journal, 2015)
The brand sold approximately $363 Million globally in 2023, having a significant growth potential with a 3Y CAGR at +5%, according to IQVIA.
In addition to this approval, Adalvo is preparing for an upcoming synchronised multi-country launch across LATAM, supported by our strong supply chain to deliver Riociguat efficiently to early markets.
At Adalvo, there are no half-measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
Partner Up Now!